391 related articles for article (PubMed ID: 26567194)
1. Potential for dietary ω-3 fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer.
Jump DB; Depner CM; Tripathy S; Lytle KA
Adv Nutr; 2015 Nov; 6(6):694-702. PubMed ID: 26567194
[TBL] [Abstract][Full Text] [Related]
2. Lipidomic and transcriptomic analysis of western diet-induced nonalcoholic steatohepatitis (NASH) in female Ldlr -/- mice.
Garcia-Jaramillo M; Spooner MH; Löhr CV; Wong CP; Zhang W; Jump DB
PLoS One; 2019; 14(4):e0214387. PubMed ID: 30943218
[TBL] [Abstract][Full Text] [Related]
3. Docosahexaenoic acid attenuates hepatic inflammation, oxidative stress, and fibrosis without decreasing hepatosteatosis in a Ldlr(-/-) mouse model of western diet-induced nonalcoholic steatohepatitis.
Depner CM; Philbrick KA; Jump DB
J Nutr; 2013 Mar; 143(3):315-23. PubMed ID: 23303872
[TBL] [Abstract][Full Text] [Related]
4. A metabolomic analysis of omega-3 fatty acid-mediated attenuation of western diet-induced nonalcoholic steatohepatitis in LDLR-/- mice.
Depner CM; Traber MG; Bobe G; Kensicki E; Bohren KM; Milne G; Jump DB
PLoS One; 2013; 8(12):e83756. PubMed ID: 24358308
[TBL] [Abstract][Full Text] [Related]
5. Docosahexaenoic acid blocks progression of western diet-induced nonalcoholic steatohepatitis in obese Ldlr-/- mice.
Lytle KA; Wong CP; Jump DB
PLoS One; 2017; 12(4):e0173376. PubMed ID: 28422962
[TBL] [Abstract][Full Text] [Related]
6. Is Western Diet-Induced Nonalcoholic Steatohepatitis in Ldlr-/- Mice Reversible?
Lytle KA; Jump DB
PLoS One; 2016; 11(1):e0146942. PubMed ID: 26761430
[TBL] [Abstract][Full Text] [Related]
7. Impact of dietary fat on the development of non-alcoholic fatty liver disease in Ldlr-/- mice.
Jump DB; Depner CM; Tripathy S; Lytle KA
Proc Nutr Soc; 2016 Feb; 75(1):1-9. PubMed ID: 26282529
[TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet.
Ganguly S; Muench GA; Shang L; Rosenthal SB; Rahman G; Wang R; Wang Y; Kwon HC; Diomino AM; Kisseleva T; Soorosh P; Hosseini M; Knight R; Schnabl B; Brenner DA; Dhar D
Cell Mol Gastroenterol Hepatol; 2021; 12(3):891-920. PubMed ID: 34062281
[TBL] [Abstract][Full Text] [Related]
9. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
[TBL] [Abstract][Full Text] [Related]
10. A Lipidomic Analysis of Docosahexaenoic Acid (22:6, ω3) Mediated Attenuation of Western Diet Induced Nonalcoholic Steatohepatitis in Male
García-Jaramillo M; Lytle KA; Spooner MH; Jump DB
Metabolites; 2019 Oct; 9(11):. PubMed ID: 31661783
[TBL] [Abstract][Full Text] [Related]
11. A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH.
Fraser DA; Wang X; Lund J; Nikolić N; Iruarrizaga-Lejarreta M; Skjaeret T; Alonso C; Kastelein JJP; Rustan AC; Kim YO; Schuppan D
J Hepatol; 2022 Apr; 76(4):800-811. PubMed ID: 34915054
[TBL] [Abstract][Full Text] [Related]
12. Different Effects of Eicosapentaenoic and Docosahexaenoic Acids on Atherogenic High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice.
Suzuki-Kemuriyama N; Matsuzaka T; Kuba M; Ohno H; Han SI; Takeuchi Y; Isaka M; Kobayashi K; Iwasaki H; Yatoh S; Suzuki H; Miyajima K; Nakae D; Yahagi N; Nakagawa Y; Sone H; Yamada N; Shimano H
PLoS One; 2016; 11(6):e0157580. PubMed ID: 27333187
[TBL] [Abstract][Full Text] [Related]
13. Potential treatment of human nonalcoholic fatty liver disease with long-chain omega-3 polyunsaturated fatty acids.
Bouzianas DG; Bouziana SD; Hatzitolios AI
Nutr Rev; 2013 Nov; 71(11):753-71. PubMed ID: 24148001
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Nonalcoholic Fatty Liver Disease with Long-Chain n-3 Polyunsaturated Fatty Acids in Humans.
Kelley NS
Metab Syndr Relat Disord; 2016 Nov; 14(9):417-430. PubMed ID: 27710160
[TBL] [Abstract][Full Text] [Related]
15. Omega-3 fatty acids and nonalcoholic fatty liver disease in adults and children: where do we stand?
Spooner MH; Jump DB
Curr Opin Clin Nutr Metab Care; 2019 Mar; 22(2):103-110. PubMed ID: 30601174
[TBL] [Abstract][Full Text] [Related]
16. n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Wang M; Ma LJ; Yang Y; Xiao Z; Wan JB
Crit Rev Food Sci Nutr; 2019; 59(sup1):S116-S129. PubMed ID: 30580553
[TBL] [Abstract][Full Text] [Related]
17. Impact of the Co-Administration of N-3 Fatty Acids and Olive Oil Components in Preclinical Nonalcoholic Fatty Liver Disease Models: A Mechanistic View.
Valenzuela R; Videla LA
Nutrients; 2020 Feb; 12(2):. PubMed ID: 32075238
[TBL] [Abstract][Full Text] [Related]
18. Docosahexaenoic acid attenuates Western diet-induced hepatic fibrosis in Ldlr-/- mice by targeting the TGFβ-Smad3 pathway.
Lytle KA; Depner CM; Wong CP; Jump DB
J Lipid Res; 2015 Oct; 56(10):1936-46. PubMed ID: 26315048
[TBL] [Abstract][Full Text] [Related]
19. Blocking integrin α
Rai RP; Liu Y; Iyer SS; Liu S; Gupta B; Desai C; Kumar P; Smith T; Singhi AD; Nusrat A; Parkos CA; Monga SP; Czaja MJ; Anania FA; Raeman R
J Hepatol; 2020 Nov; 73(5):1013-1022. PubMed ID: 32540177
[TBL] [Abstract][Full Text] [Related]
20. Time course of western diet (WD) induced nonalcoholic steatohepatitis (NASH) in female and male Ldlr-/- mice.
Spooner MH; Garcia-Jaramillo M; Apperson KD; Löhr CV; Jump DB
PLoS One; 2023; 18(10):e0292432. PubMed ID: 37819925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
